| To date, few effective treatments have been offered. Pan retinal photocoagulation is the preferred treatment option for the
treatment of critical NPDR. This approach, however, will maintain visual acuity only and could be interfere with other
sight skills (such as ability to drive); also, the assessment of recurrence after therapy maintains huge. As a result, the
development of local NPDR therapy is important to prevent the disease from progressing to a point where it may have a
significant impact on visual acuity. The purpose of this study was to determine how intravitreal conbercept injections work
in non-proliferative diabetic retinopathy. The study included patients with type 2 diabetes, medication-controlled blood
sugar levels, glycosylated haemoglobin levels below 10 percent, then bp below 160/90 mmHg, respectively. The research
comprised a total of 54 individuals with NPDR (26 men and 28 women; mean age, 60.1 8.3 years). A total of 54 eyes were
chosen from the 54 patients, including 30 right eyes and 24 left eyes. The baseline patient characteristics are shown in
Table 1. At baseline, the mean BCVA was 0.71 0.20 logMAR, and the mean CFT was 424.26 64.89. For diabetic
retinopathy, anti-VEGF medication has lately become a prominent therapeutic choice. Anti-VEGF injections into the eyes
have been used to treat 22 vision-threatening diseases. 23 This vision-saving procedure is especially beneficial to patients
with diabetic retinopathy. In afflicted individuals, intravitreal conbercept injection exhibited a clear and persistent
therapeutic effect on NPDR, according to our data. However, a more thorough investigation of the therapeutic mechanism
is needed.ddd |
